Immatics (IMTX) Filings

6-K

IMTX Immatics N.V

21 Mar 23

Current report (foreign)

6:03am

6-K

IMTX Immatics N.V

13 Mar 23

Current report (foreign)

6:30am

SC 13G/A

Nantahala Capital Management, LLC

14 Feb 23

Immatics / Nantahala Capital Management ownership change

5:02pm

SC 13G/A

IMTX Immatics N.V

14 Feb 23

Immatics / BAKER BROS. ADVISORS ownership change

4:00pm

SC 13G/A

IMTX Immatics N.V

10 Feb 23

Immatics / dievini Hopp BioTech holding GmbH & Co KG ownership change

4:01pm

SC 13G

IMTX Immatics N.V

7 Feb 23

Immatics / WELLINGTON MANAGEMENT ownership change

12:00am

6-K

IMTX Immatics N.V

9 Jan 23

Current report (foreign)

7:05am

6-K

IMTX Immatics N.V

17 Nov 22

Current report (foreign)

7:13am

6-K

IMTX Immatics N.V

10 Nov 22

Next-Generation TCR Bispecifics (TCER) Targeting Peptide-HLA Antigens for the Treatment of Patients with Solid Tumors

9:10am

6-K

IMTX Immatics N.V

18 Oct 22

Current report (foreign)

8:05am

6-K

IMTX Immatics N.V

12 Oct 22

Immatics Announces $110 Million Underwritten Offering of Ordinary Shares

10:55am

424B5

IMTX Immatics N.V

11 Oct 22

Prospectus supplement for primary offering

6:30am

424B5

IMTX Immatics N.V

11 Oct 22

Prospectus supplement for primary offering

6:03am

6-K

IMTX Immatics N.V

11 Oct 22

Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME

6:02am

6-K

IMTX Immatics N.V

12 Sep 22

Current report (foreign)

7:00am

6-K

IMTX Immatics N.V

23 Aug 22

Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME

7:12am

6-K

IMTX Immatics N.V

9 Aug 22

Current report (foreign)

7:05am

6-K

IMTX Immatics N.V

30 Jun 22

Current report (foreign)

7:06am

S-8

IMTX Immatics N.V

24 Jun 22

Registration of securities for employees

4:06pm